글로벌 신경계 질환 약물 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모                              

전 세계적으로 신경계 질환이 사망의 주요 원인입니다. 중추 신경계와 말초 신경계 질환으로 정의됩니다. 이 질병은 주로 노인 인구에게 영향을 미칩니다. 진행되어 장기 치료가 필요할 수 있습니다. 선천적 신경계 이상은 배아 발달 초기 단계에 나타나며 출생 시 발견할 수 있습니다. 외상성 뇌 손상, 면역 문제, 산후 주사, 척수 손상, 신생물, 주변 화학 물질이나 독극물에 노출되는 등 다양한 요인이 출생 후 후천성 신경계 질환을 일으킬 수 있습니다. 많은 박테리아, 바이러스, 진균 및 기생충 질병이 신경계를 손상시켜 신경계 질환을 일으킬 수 있습니다.

Data Bridge Market Research는 신경계 질환 약물 시장이 2021년에 794억 달러 규모였으며 2029년까지 1,256억 달러에 도달할 것으로 예상되며 2022년에서 2029년까지의 예측 기간 동안 5.9%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

보고 범위 및 시장 세분화

시장 정의

신경계 질환은 뇌 또는 신경계의 어느 부분이든 제대로 작동하지 않아 신체적 및/또는 심리적 증상이 나타날 때 발생합니다. 신경계 질환은 항정신병제, 항경련제, 항콜린제, 진통제를 포함한 다양한 약물로 치료합니다. 또한 처방되는 약물은 주로 환자의 신경계 상태에 따라 결정됩니다. 이러한 약물은 신경계 질환 관리, 증상 감소, 삶의 질 향상에 도움이 됩니다. 다발성 경화증을 치료하고 염증을 줄이는 데 널리 사용되는 코르티코스테로이드는 가장 일반적으로 사용되는 신경계 약물 중 하나입니다.

신경계 질환 약물 시장 동향

운전자

• 노령 인구 증가

시장 성장은 노인 인구의 증가로 인해 촉진되며, 이로 인해 수많은 신경학적 문제가 발생합니다. 뇌졸중 및 편두통과 같은 뇌혈관 질환은 독일, 영국, 이탈리아를 포함한 모든 연령대의 사람들에게 영향을 미칩니다. 45~84세 성인의 경우 프랑스, ​​스웨덴, 그리스, 덴마크, 러시아는 뇌혈관 질환의 발병률이 높습니다. 2018년 NCBI에 발표된 연구에 따르면 싱가포르의 뇌졸중 유병률은 65세 이상 인구의 7.67%였습니다.

• 의료 인프라에 대한 투자 증가

피부염 시장의 성장률에 영향을 미치는 또 다른 중요한 요인은 인프라를 개선하는 데 도움이 되는 의료비 지출 증가입니다. 또한, 다양한 정부 기관은 자금을 늘려 의료 인프라를 개선하고자 하며, 이는 시장 역학에 더욱 영향을 미칠 것입니다.

• 조기 질병 진단에 대한 인식 증가

The neurological disorder drugs market is expected to grow due to rising awareness associated with early disease diagnosis through awareness campaigns by government regulatory bodies and private organizations, and market entry of efficient drugs in the near future, owing to the presence of a strong drug pipeline. As per a report published by the Pharmaceutical Research and Manufacturers of America (PhRMA) in April 2018, biopharmaceutical companies in the United States are currently developing 537 medications for various neurological illnesses. 95 drugs for brain tumors, 46 for chronic pain, and 92 for Alzheimer's disease are among them. Multiple sclerosis, migraines, amyotrophic lateral sclerosis, and Parkinson's disease are among the 30 illnesses being researched.

Furthermore, surging number of government initiatives to spread awareness and increasing prevalence of neurological diseases such as dementia will result in the expansion of neurological disorder drugs market. Along with this, sedentary lifestyle of people and will enhance the growth rate of the market.

Opportunities

• Development of new drugs   

Moreover, the market's growth is fueled by an increase in the development of new drugs. This will provide beneficial opportunities for the market growth. Brain injuries and neurological disorders are among the major causes of death around the world. As a result, researchers are pursuing chances to produce new medications that could improve the treatment of neurological disorders by altering glucose metabolism. For instance, Gero Discovery, a provider of novel therapeutic alternatives for neurodegenerative disorders, recently revealed the discovery of a prospective medicine that uses the technique of glucose metabolism alteration in stressed neurons to assist avoid neuronal death. To create novel treatments, companies in the neurological disorder drugs industry need work with qualified researchers.

• Increase in the number of research and development activities       

The increase in the number of research and development activities is estimated to provide various beneficial opportunities for the neurological disorder drugs market’s growth. New therapeutic techniques for the treatment of Parkinson's disease are being adopted by companies in the neurological disorder pharmaceuticals market. This leads to high number of research activities to better understand the disease's genetic risk factors in order to find better drugs. As a result, mutations in the GBA1 gene are emerging as a prospective therapeutic development strategy. Mutations in the gene, however, may cause GCase (glucocerebrosidase) enzyme deficiencies. As a result, manufacturers in the neurological disorder pharmaceuticals market are concentrating on activating wild type GCase in order to produce new therapeutic molecules for the treatment of Parkinson's disease.

Moreover, the market's growth is fueled by rising investment for the development of advanced technologies and increase in the number of emerging markets. These factors will provide beneficial opportunities for the neurological disorder drugs market growth.

Restraints/Challenges

On the other hand, high cost associated with the research and development activities will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the neurological disorder drugs market. Additionally, product recalls and strict government regulations will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This neurological disorder drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neurological disorder drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Neurological disorder drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Recent Development

• In September 2021, Sumitomo Dainippon Pharma and Otsuka had announced a collaboration as well as license agreement for four psychiatry and neurology compounds namely ulotaront (SEP-363856), SEP-4199, SEP-378614, and SEP-380135. Under the terms of the partnership, Sunovion and Otsuka will split the costs and revenues of clinical trials, regulatory applications, and commercialization in each of these nations and areas. Additional ulotaront indications, and also SEP-378614 and SEP-380135 indications, will be identified after future Sumitomo Dainippon Pharma Group and Otsuka consultations.

Global Neurological Disorder Drugs Market Scope

The neurological disorder drugs market is segmented on the basis of indication, drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Epilepsy
• Alzheimer’s Disease
• Parkinson’s Disease
• Multiple Sclerosis
• Cerebrovascular Disease
• Others

Drug Class

• Cholinesterase Inhibitors
• NMDA Receptor Antagonists
• Antiepileptic
• Antipsychotic and Antidepressant
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Neurological Disorder Drugs Market Regional Analysis/Insights

The neurological disorder drugs market is analysed and market size insights and trends are provided by country, indication, drug class, route of administration, end-users and distribution channel as referenced above.

The countries covered in the neurological disorder drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the neurological disorder drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of prevalence of neurological disorder and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, growing presence of major key players and increase in number of FDA approval drugs will further propel the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to high presence of generic manufacturer in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Neurological Disorder Drugs Market Share Analysis

신경계 질환 약물 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 신경계 질환 약물 시장과 관련된 회사의 초점에만 관련이 있습니다.

신경계 질환 약물 시장에서 활동하는 주요 업체는 다음과 같습니다.

• 머크 KGaA(독일)
• 에자이 주식회사(일본)
• 아스트라제네카(영국)
• 사노피(프랑스)
• 노바티스 AG(스위스)
• 애벗(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• Teva Pharmaceutical Industries Ltd. (아일랜드)
• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)
• WOCKHARDT(뭄바이)
• Novo Nordisk A/S(덴마크)
• Glenmark Pharmaceuticals Limited(인도)
• 시플라 주식회사(미국)
• Bausch Health Companies Inc. (캐나다)
• 오츠카 아메리카 제약 주식회사(미국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 다케다제약 주식회사(일본)
• 스미토모 주식회사(일본)
• Biocon(인도)

SKU-53290